Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intensified Rituximab, Methotrexate, Procarbazine, and Cytarabine (R-MPVA) Regimen With Sequential Addition of Etoposide to R-MPV and Ifosfamide to R-AraC for Newly Diagnosed Primary CNS Lymphoma Patients Aged Between 60 and 70 Years: An LOC Network Study.

Hematological oncology·2026
Same author

Radiological and FDG-PET imaging features of Epstein-Barr virus-positive primary central nervous system lymphomas.

Journal of neurology·2026
Same author

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.

Haematologica·2026
Same author

CAR T-Cell Therapy in Patients With Primary Central Nervous System Lymphoma: A LOC Network Study.

American journal of hematology·2026
Same author

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.

HemaSphere·2026

Related Experiment Video

Updated: Jan 9, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.2K

Large B-cell lymphoma: The LYSA pragmatic guidelines.

Pierre Sesques1, Guillaume Manson2, Sydney Dubois3

  • 1Department of Hematology, Hospices Civils de Lyon, Hopital Lyon-Sud, Claude Bernard Lyon 1 University, Lyon, France.

European Journal of Cancer (Oxford, England : 1990)
|December 6, 2025
PubMed
Summary

Recent advancements in large B-cell lymphoma (LBCL) management include new therapies and improved diagnostics. This article provides pragmatic guidelines for optimal diagnosis, staging, and treatment of LBCL, enhancing patient outcomes.

Keywords:
GuidelinesLYSALarge B-cell lymphomaLevel of evidence

More Related Videos

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.2K

Related Experiment Videos

Last Updated: Jan 9, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.2K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.2K

Area of Science:

  • Hematology
  • Oncology
  • Clinical Medicine

Background:

  • Large B-cell lymphomas (LBCL) management has evolved significantly in the past five years.
  • New therapeutic options, including immunotherapies, cell therapies, and targeted molecules, have emerged.
  • Improved understanding of LBCL biology and enhanced diagnostic tools have advanced patient care.

Purpose of the Study:

  • To present pragmatic guidelines for the management of large B-cell lymphomas (LBCL).
  • To integrate the latest evidence from clinical trials, expert consensus, and real-world practice.
  • To provide clinicians with a framework for optimizing LBCL patient care.

Main Methods:

  • Development of guidelines by the Lymphoma Study Association (LYSA).
  • Inclusion of key aspects: diagnosis, staging, response evaluation, and treatment.
  • Integration of evidence from clinical trials, expert consensus, and real-world data.

Main Results:

  • Guidelines address diagnosis, staging, response evaluation, and treatment strategies for LBCL.
  • The guidelines incorporate recent therapeutic advances and biological insights.
  • Focus on balancing treatment efficacy and toxicity for optimal patient outcomes.

Conclusions:

  • The LYSA guidelines offer a practical framework for managing LBCL.
  • These guidelines aim to translate the best available evidence into clinical practice.
  • Optimized care through evidence-based strategies is expected to enhance patient outcomes in LBCL.